BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 30474703)

  • 1. Prevalence of TPMT, ITPA and NUDT 15 genetic polymorphisms and their relation to 6MP toxicity in north Indian children with acute lymphoblastic leukemia.
    Khera S; Trehan A; Bhatia P; Singh M; Bansal D; Varma N
    Cancer Chemother Pharmacol; 2019 Feb; 83(2):341-348. PubMed ID: 30474703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimal predictor for 6-mercaptopurine intolerance in Chinese children with acute lymphoblastic leukemia: NUDT15, TPMT, or ITPA genetic variants?
    Zhou H; Li L; Yang P; Yang L; Zheng JE; Zhou Y; Han Y
    BMC Cancer; 2018 May; 18(1):516. PubMed ID: 29720126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Role of TPMT, ITPA, and NUDT15 Variants during Mercaptopurine Treatment of Swedish Pediatric Patients with Acute Lymphoblastic Leukemia.
    Wahlund M; Nilsson A; Kahlin AZ; Broliden K; Myrberg IH; Appell ML; Berggren A
    J Pediatr; 2020 Jan; 216():150-157.e1. PubMed ID: 31635813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of TPMT and ITPA variants in mercaptopurine disposition.
    Gerbek T; Ebbesen M; Nersting J; Frandsen TL; Appell ML; Schmiegelow K
    Cancer Chemother Pharmacol; 2018 Mar; 81(3):579-586. PubMed ID: 29387964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myelotoxicity after high-dose methotrexate in childhood acute leukemia is influenced by 6-mercaptopurine dosing but not by intermediate thiopurine methyltransferase activity.
    Levinsen M; Rosthøj S; Nygaard U; Heldrup J; Harila-Saari A; Jonsson OG; Bechensteen AG; Abrahamsson J; Lausen B; Frandsen TL; Weinshilboum RM; Schmiegelow K
    Cancer Chemother Pharmacol; 2015 Jan; 75(1):59-66. PubMed ID: 25347948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NUDT15 and TPMT genetic polymorphisms are related to 6-mercaptopurine intolerance in children treated for acute lymphoblastic leukemia at the Children's Cancer Center of Lebanon.
    Zgheib NK; Akika R; Mahfouz R; Aridi CA; Ghanem KM; Saab R; Abboud MR; Tarek N; El Solh H; Muwakkit SA
    Pediatr Blood Cancer; 2017 Jan; 64(1):146-150. PubMed ID: 27577869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Childhood acute lymphoblastic leukemia mercaptopurine intolerance is associated with NUDT15 variants.
    Wang DS; Yu CH; Lin CY; Chang YH; Lin KH; Lin DT; Jou ST; Lu MY; Chang HH; Lin SW; Chen HY; Yang YL
    Pediatr Res; 2021 Jan; 89(1):217-222. PubMed ID: 32221476
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Puangpetch A; Tiyasirichokchai R; Pakakasama S; Wiwattanakul S; Anurathapan U; Hongeng S; Sukasem C
    Pharmacogenomics; 2020 Apr; 21(6):403-410. PubMed ID: 32308129
    [No Abstract]   [Full Text] [Related]  

  • 9. Dosage of 6-Mercaptopurine in Relation to Genetic TPMT and ITPA Variants: Toward Individualized Pediatric Acute Lymphoblastic Leukemia Maintenance Treatment.
    Kouwenberg TW; van den Bosch BJC; Bierau J; Te Loo DMWM; Coenen MJH; Hagleitner MM
    J Pediatr Hematol Oncol; 2020 Mar; 42(2):e94-e97. PubMed ID: 31895215
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Fan POL; Leung KT; Chan KYY; Leung AWK; Lam GKS; Chow TTW; Cheng FWT; Yuen LYP; Moriyama T; Yang JJ; Li CK
    Pediatr Hematol Oncol; 2022 Apr; 39(3):254-266. PubMed ID: 34665987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of TPMT and ITPA gene polymorphisms and effect on mercaptopurine dosage in Chilean children with acute lymphoblastic leukemia.
    Farfan MJ; Salas C; Canales C; Silva F; Villarroel M; Kopp K; Torres JP; Santolaya ME; Morales J
    BMC Cancer; 2014 Apr; 14():299. PubMed ID: 24774509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epistatic interactions between thiopurine methyltransferase (TPMT) and inosine triphosphate pyrophosphatase (ITPA) variations determine 6-mercaptopurine toxicity in Indian children with acute lymphoblastic leukemia.
    Dorababu P; Nagesh N; Linga VG; Gundeti S; Kutala VK; Reddanna P; Digumarti R
    Eur J Clin Pharmacol; 2012 Apr; 68(4):379-87. PubMed ID: 22009189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging role of NUDT15 polymorphisms in 6-mercaptopurine metabolism and dose related toxicity in acute lymphoblastic leukaemia.
    Singh M; Bhatia P; Khera S; Trehan A
    Leuk Res; 2017 Nov; 62():17-22. PubMed ID: 28963908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacogenetics of 6-mercaptopurine in a black Zimbabwean cohort treated for acute lymphoblastic leukaemia.
    Chikondowa P; Munkombwe D; Chikwambi Z; Kuona P; Masimirembwa C
    Pharmacogenomics; 2023 Jun; 24(8):449-457. PubMed ID: 37248698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic polymorphism of inosine-triphosphate-pyrophosphatase influences mercaptopurine metabolism and toxicity during treatment of acute lymphoblastic leukemia individualized for thiopurine-S-methyl-transferase status.
    Stocco G; Crews KR; Evans WE
    Expert Opin Drug Saf; 2010 Jan; 9(1):23-37. PubMed ID: 20021291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Additive effects of TPMT and NUDT15 on thiopurine toxicity in children with acute lymphoblastic leukemia across multiethnic populations.
    Maillard M; Nishii R; Yang W; Hoshitsuki K; Chepyala D; Lee SHR; Nguyen JQ; Relling MV; Crews KR; Leggas M; Singh M; Suang JLY; Yeoh AEJ; Jeha S; Inaba H; Pui CH; Karol SE; Trehan A; Bhatia P; Antillon Klussmann FG; Bhojwani D; Haidar CE; Yang JJ
    J Natl Cancer Inst; 2024 May; 116(5):702-710. PubMed ID: 38230823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Classification and regression tree-based prediction of 6-mercaptopurine-induced leucopenia grades in children with acute lymphoblastic leukemia.
    Naushad SM; Dorababu P; Rupasree Y; Pavani A; Raghunadharao D; Hussain T; Alrokayan SA; Kutala VK
    Cancer Chemother Pharmacol; 2019 May; 83(5):875-880. PubMed ID: 30806759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Severe 6-mercaptopurine-induced hematotoxicity in childhood an ALL patient with homozygous NUDT15 missence variants].
    Kimura S; Hasegawa D; Yoshimoto Y; Hirabayashi S; Hosoya Y; Yoshihara H; Kumamoto T; Tanaka Y; Manabe A
    Rinsho Ketsueki; 2016 Jun; 57(6):748-53. PubMed ID: 27384855
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive characterization of pharmacogenetic variants in TPMT and NUDT15 in children with acute lymphoblastic leukemia.
    Moriyama T; Yang W; Smith C; Pui CH; Evans WE; Relling MV; Bhatia S; Yang JJ
    Pharmacogenet Genomics; 2022 Feb; 32(2):60-66. PubMed ID: 34412101
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effect of genetic polymorphism of TPMT and NUDT15 on the tolerance of 6-mercaptopurine therapy in adult acute lymphoblastic leukemia].
    Hao QS; Wang Z; Fang QY; Gong XY; Liu KQ; Li Y; Wei H; Wang Y; Li QH; Wang M; Tian Z; Wang JX; Mi YC
    Zhonghua Xue Ye Xue Za Zhi; 2021 Nov; 42(11):911-916. PubMed ID: 35045652
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.